To identify myocilin (TIGR/MYOC) properties that are specific to the human trabecular meshwork (HTM). To search for genes highly expressed in dexamethasone (DEX)-induced HTM cells that are barely expressed or absent in DEX-induced cells from other tissues.
T he glaucomas are a group of diseases characterized by progressive degeneration of the optic nerve, usually accompanied by elevated intraocular pressure (IOP). They affect 70 million people worldwide and are the leading cause of blindness among African Americans. 1 Recently, mutations in TIGR/MYOC, also known as trabecular meshwork inducible glucocorticoid response protein (TIGR), have been linked to several types of glaucoma. [2] [3] [4] Although the function of this gene is currently unknown, genetic linkage analysis has demonstrated the presence of more than 25 distinct mutations in families with the most prevalent form of glaucoma, primary open-angle glaucoma (POAG), and in those with a rare, earlyonset form, juvenile open-angle glaucoma (JOAG). 5 TIGR/MYOC was identified as a protein upregulated in the HTM after long-term treatment with DEX 6 -8 and was independently discovered in ciliary body 9 and normal human retina. 10 Some investigators believe its induction by DEX correlates with the time course and development of steroid-induced glaucoma, 8, 11 a condition occurring in 30% to 40% of patients who are treated with steroids. 12 Because steroid-induced glaucoma mimics many aspects of POAG, it may be an important model for study of the disease. Mutations in TIGR/MYOC, however, are not implicated in causing or increasing susceptibility to steroid-induced glaucoma. 13, 14 TIGR/MYOC is a 504-amino-acid secretory protein translated from three exons. The amino terminal domain contains Nand O-glycosylation sites and a leucine zipper, and it is 25% homologous to the heavy chain of myosin. TIGR/MYOC is glycosylated 8, 15 and the glycosylated and nonglycosylated protein forms migrate at approximately 57 and 55 kDa, respectively, on SDS-PAGE. 15 Most glaucoma-linked mutations in TIGR/MYOC are located at its C-terminal end, in the region known as the olfactomedin (OLF) domain because of its 40% homology to olfactomedin, an extracellular matrix (ECM) protein first described in bullfrog olfactory epithelium. 16 Recent studies have demonstrated that many missense and nonsense mutations affecting the OLF domain impair secretion of the TIGR/MYOC mutant protein. 17, 18 The impairment of secretion appears to be due to an inefficient processing of the mutant protein that results in misfolding and accumulation of aggregates inside the cell. 15 These results have lead us to postulate that the association of TIGR/MYOC mutants with glaucoma may be through a gain of deleterious function, 15 an idea supported by the findings that heterozygous and homozygous Myoc-knockout mice are viable and fertile, have normal IOP, and exhibit normal ocular morphology. 19 The expression of TIGR/MYOC may be under the control of its 5-kb promoter region, which contains 13 predicted hormone-response elements and includes several glucocorticoidresponse elements (GREs). 6, 8, 20 It has also been reported that multiple GRE half-sites exist within the 1900-bp region upstream of the putative translation start site. 21 Some of these half-sites have been described in systems in which there is delayed induction of glucocorticoid-induced gene expression. 22 It has been proposed that the delayed induction of TIGR/MYOC could be the result of classic GREs far upstream, the nearer GRE half-sites, or a secondary response to steroids. 21 More recent studies examining the promoter's effects in luciferase reporter gene assay systems show that certain regions of putative GREs are not responsive to treatment with DEX 20 and that TIGR/MYOC is a delayed glucocorticoid-responsive gene in which the glucocorticoid receptor indirectly affects expression. 23 Thus, the described GREs in the promoter may not be directly responsible for upregulation of DEX, and distinct factors specifically present in DEX-induced HTM may first be required to stimulate expression of TIGR/MYOC. To date, these factors have not been described.
TIGR/MYOC is highly expressed and secreted in the TM but is also found in many other tissues of the body, including skeletal muscle, retina, 9 and ONH astrocytes. 24, 25 However, mutations in TIGR/MYOC are only linked to glaucoma and do not seem to affect the function of any other organ. This fact may be an indication that TIGR/MYOC serves TM-specific functions and/or has TM-specific properties that could be integral to glaucoma pathophysiology. In this study, we compared TIGR/MYOC expression, induction, secretion, and posttranslational processing in several selected human cell types. In an effort to identify TM glucocorticoid factors that either directly modulate IOP or affect TIGR/MYOC levels only in the TM, we used gene array technology. To select against genes upregulated by DEX in non-TM tissues, we compared the expression profile of HTM-DEX cells with another DEX-induced cell line, ONH astrocytes. Our choice of ONH astrocytes was based on their relevance in degeneration of the ONH in glaucoma, 26 the presence of detectable levels of TIGR/MYOC in vivo, 24 and our own result of the absence of DEX-induced TIGR/MYOC in these cells. In addition, because of the delayed glucocorticoid response of TIGR/MYOC, we chose to compare DEX induction after longer periods of drug treatment.
MATERIALS AND METHODS

Cell Culture
To examine the properties of TIGR/MYOC in different cell types, we chose several human cell lines based on their characteristics. HTM cells were used as a positive point of reference. Human umbilical vein endothelial cells (HUVECs) were chosen for their endothelial nature and because they are well described in the literature. Human embryonic skeletal muscle cells (SkMCs) and ONH astrocytes were chosen as representatives of other tissues with previously reported TIGR/MYOC expression. 9, 27, 28 HeLa cells were used as an unrelated, transformed cell line.
The procedures in this study adhered to the provisions of the Declaration of Helsinki for research in human tissue. HTM cell lines used in these experiments were derived from two different donors with no history of glaucoma (HTM40 and HTM41). Primary cultures were established from donor eyes obtained from national eye banks within 48 hours of death. The TM from each of the donor eyes was isolated from surrounding tissue with incisions both anterior and posterior to the meshwork and treated with collagenase, as previously described. 29 Briefly, the explanted tissue was placed on 2% gelatincoated 35-mm dishes and improved minimal essential medium (IMEM; Biofluids, Rockville, MD) supplemented with 20% fetal bovine serum (FBS) (Gibco BRL, Rockville, MD) and 50 g/mL gentamicin (Gibco BRL). Cells that grew from digested tissue were first-passaged 1:4 at 2 to 3 weeks after explantation and subsequently propagated in the same medium with 10% serum. Each cell line survived for approximately 8 to 10 passages. For the current experiments, HTM cells were used at passages 4 to 6. HUVECs and HeLa cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Human embryonic SkMCs were obtained from Clonetics (Walkersville, MD). HUVECs were maintained in endothelial cell medium EBM-2 basal medium with EGM-2 SingleQuots supplements and growth factors from Clonetics (Walkersville, MD). HeLa cells were maintained in IMEM supplemented with 10% FBS, 50 g/mL gentamicin, and 100 M nonessential amino acid solution (Gibco BRL). SkMCs were maintained in the provider's medium (Clonetics).
ONH astrocytes (line 00-1LLS) were grown and characterized from two normal eyes (aged 15 years) with no history of eye disease, diabetes, or neurodegenerative disease, as previously described in detail. 30, 31 Briefly, four explants from each human lamina cribrosa were dissected and freed from sclera and surrounding tissues. Each explant was placed into a 25-cm 2 tissue culture flask (Primaria; Falcon-BD Biosciences, Lincoln Park, NJ) and maintained in Dulbecco's modified Eagle's medium (DMEM)/Ham's F-12 (Washington University Medical School Tissue Culture Support Center, St. Louis, MO) supplemented with 10% FBS (BioWhittaker, Walkersville, MD) and PSFM (10,000 U/mL penicillin, 10,000 g/mL streptomycin, and 25 g/mL amphotericin B; Gibco BRL). Cells were kept in a 37°C, 5% CO 2 incubator. After 2 to 4 weeks, using a modified immunopanning procedure described by Mi and Barres, 32 we obtained purified primary cultures. To select ONH (type 1B) astrocytes, cell suspensions from the primary cultures were placed on a P100 panning dish coated with C5 anti-neuroepithelial antibody (1:20, gift from Ben Barres, Stanford University, Stanford, CA) and incubated at room temperature for 30 minutes. After the nonadherent cells were removed, the attached cells were grown for 1 to 2 weeks in DMEM/Ham's F-12 with 10% FBS in the incubator. Cultured ONH astrocytes were characterized by positive immunostaining for both glial fibrillary acidic protein (GFAP) and neural cell adhesion molecule (NCAM), as described. 30 For these experiments, third-passage cells were grown and maintained in DMEM/ Ham's F-12 (Gibco BRL), 10% FBS, and 50-g/mL gentamicin.
RNA Extraction and Northern Blot Hybridization
Cell cultures were grown to confluence in 10-cm plates and treated with DEX (Sigma, St. Louis, MO) for 10 days at a concentration of 10 Ϫ7 M. DEX was prepared in absolute ethanol at 0.1 mM and diluted 1000-fold into fresh complete IMEM every other day for the duration of the experiment. At the end of 10 days, both control and treated sample RNAs were extracted with a kit (RNeasy Mini Kit; Qiagen, Valencia, CA). RNA molecules selectively bound to the silica gel base were eluted with 50 L RNase-free water. RNA from each sample was lyophilized to dryness, denatured in 50% formamide, and separated by 2.2 M formaldehyde, 1.25% agarose, 0.05 M 3-[N-morpholino] propane sulfonic acid (MOPS), and 1 mM EDTA gel electrophoresis. After electrophoresis, gels were washed with dH 2 0 for 30 minutes and transferred to a nitrocellulose membrane (Schleicher & Schuell, Keene, NH) overnight by capillary action with 10ϫ sodium saline citrate (SSC). After the transfer, UV cross-linked blots were prehybridized at 42°C for 6 to 12 hours in a buffer containing 50% formamide, 5ϫ SSC, 5ϫ Denhardt's, 50 mM NaP0 4 (pH 7.4), 0.1% sodium dodecyl sulfate (SDS) with 50 g/mL sheared salmon sperm DNA (Research Genetics, Huntsville, AL). The filters were then placed in fresh buffer, hybridized overnight to 1 to 5 ϫ 10 6 cpm/mL of random-primer-labeled TIGR/ MYOC cDNA (Roche Molecular Biosystems, Indianapolis, IN) at the same temperature. The TIGR/MYOC cDNA probe used in the hybridization experiments contained 1603 base pairs and was obtained by PCR amplification of pMC2 15 with primers 5Ј-AGCTTTGTTTAAACGC-CTCACCAAGCCTCTGCAA-3Ј (59 -78 nucleotides [nt] TIGR/MYOC cDNA) and 5Ј-GGCGGATCCTGCCATTGCCTGTACAGCTTGGAG-3Ј (1597-1621 nt TIGR/MYOC cDNA) followed by gel purification of the fragment with a PCR purification kit (QIAquick; Qiagen). After hybridization, filters were washed five times (15-20 minutes each): four times in 2ϫ SSC-1% SDS (two at room temperature [RT] and two at 52°C) and once in 2ϫ SSC at 52°C. Exposure was conducted using x-ray film (BioMax MR; Scientific Imaging Systems, Eastman Kodak, New Haven, CT) at Ϫ80°C with intensifying screens. To monitor RNA degradation and loading, filters were subsequently rehybridized to 2 ϫ 10 6 cpm/mL of 28S oligonucleotide at 42°C for 2 hours, washed twice in 2ϫ SSC-1% SDS (one at RT, one at 37°C) and exposed at RT. 33 Protein extracts were separated by 10% SDS-PAGE and electrotransferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA). After blocking with 5% nonfat dry milk in PBS-0.2% Tween 20 (Sigma) for 2 hours, the membranes were incubated overnight at 4°C with rabbit polyclonal TIGR/MYOC antibodies. 35 Immunoreactive bands were visualized by chemiluminescence (ECL Plus; Amersham Pharmacia Biotech, Piscataway, NJ) after treatment with anti-rabbit IgG secondary antibodies conjugated to horseradish peroxidase (1:8000; Pierce, Rockford, IL). For the loading control, blots were reprobed with a mouse monoclonal ␤-tubulin antibody (clone TUB 2.1, 1:1000; Sigma) and visualized with conjugated horseradish peroxidase under the same conditions. Gels were run with equivalent volumes of the total cell extract samples and their corresponding supernatants.
Recombinant Adenoviruses and their Delivery to Tissue Culture Cells
Replication-deficient recombinant adenoviral expression vectors encoding full-length TIGR/MYOC (AdhTIG3) and a truncated mutant TIGR/MYOC (AdhTIG1, Thr345STOP) were constructed and purified as previously described. 15 For gene delivery, cell cultures were grown to confluence in 35-mm wells, washed twice with PBS, and exposed to 25 to 100 plaque forming units (pfu)/cell of either AdhTIG3 or AdhTIG1 for 1 hour in 1 mL serum-free medium. After exposure to the virus, 1 mL IMEM-5% FBS was added to the medium and incubation continued for 48 hours. Proteins from the medium and cell monolayer were then extracted and analyzed as described earlier. Control dishes were treated with the same volume of viral vehicle under identical conditions.
Gene Microarray Analysis
Early passages of HTM cell lines HTM-40 and HTM-41 and two separate dishes of 00-1LLS ONH astrocytes were treated with 10 Ϫ7 M DEX for 6 to 8 days. Total RNA from each of the four experiments was extracted as described earlier. The targets for the DNA microarray analysis were prepared according to the manufacturer's instructions (Human Genome U95Av2 GeneChip microarrays, n ϭ 6; Affymetrix, Santa Clara, CA) at the Duke University Microarray Facility. These microarrays contain oligonucleotide probes representing 12,627 genes, in which each gene is represented by a probe set consisting of 16 to 20 probes. Arrays were hybridized to the targets at 45°C for 16 hours and then washed and stained, by using the staining station according to the manufacturer's instructions (GeneChip Fluidics; Affymetrix). DNA chips were scanned (GeneChip Scanner; Affymetrix), and signals obtained by scanning were processed by the accompanying software (Microarray Suite, ver.4.0; Affymetrix). The absolute analysis determines whether transcripts represented on the array are detected in the sample (transcripts present, marginal, or absent). It uses a variety of metrics, including background and noise calculations, based on the hybridization intensities measured by the scanner. The comparison analysis determines the relative change in abundance for each transcript between a baseline and an experimental sample (fold change). It also uses a variety of metrics, including normalization and scaling factors, based on the intensity differences between each baseline and experimental probe set. The program normalizes expression values against the internal control and eliminates genes absent in both chips from the comparisons. Listed fold change values of Ϯ2 are significant. To search for genes located at chromosomal regions linked to glaucoma, each of the selected genes was chromosome mapped using the Locus Link database (http://www.ncbi.nlm.nih.gov/LocusLink/). Each of the obtained chromosomal regions was then manually matched for glaucoma by using known glaucoma-associated loci acquired in the OMIM Morbid Map database (http://www.ncbi.nlm.nih.gov/Omim/ searchmorbid/, provided in the public domain by the National Center for Biotechnology Information, Bethesda, MD).
Relative Quantitative Reverse Transcription-Polymerase Chain Reaction (RQ RT-PCR)
Reverse transcription (RT) reactions were performed with a kit (Retroscript; Ambion). One microgram total RNA was mixed with 2 L of 50 M random decamers and nuclease-free water in a total of 12 L, heated at 75°C for 2 minutes, and cooled on ice. The reaction was continued in a 20-L reaction mixture containing 10 L of 10ϫ RT buffer (500 mM Tris-HCl [pH8.3], 750 mM KCl, 30 mM MgCl 2 , and 50 mM DTT), 4 L dNTPs (2.5 mM each), 1 L RNase inhibitor (10 U), and 1 L Moloney murine leukemia virus (M-MuLV) reverse transcriptase (100 U). The RT reactions were incubated at 42°C for 60 minutes and terminated at 92°C for 2 minutes. A 2.5-L aliquot of RT reaction was used for amplification by PCR, which was performed in a 50-L reaction mixture containing 5 L 10ϫ PCR buffer (400 mM Tricine-KOH [pH 9.2], 150 mM KOAc, 35 mM Mg(OAc) 2 , and 37 g/mL bovine serum albumin), 4 L dNTPs (2.5 mM each), 4 L of the gene primer-specific mix (5 M each forward and reverse primer) and 1 L cDNA polymerase mix (Advantage; Clontech, Palo Alto, CA). The PCR mixture was split into four tubes, and amplification was performed as follows: 94°C, 4 minutes and cycles of 94°C for 30 seconds, 60°C for 30 seconds, and 72°C for 60 seconds. For each primer pair, the linear range of the PCR reaction was determined by varying the number of cycles in each of the four tubes. RT-PCR products were electrophoresed on 2% agarose gels containing 25 ng/mL ethidium bromide. To eliminate the possibility of amplifying genomic DNA, primer pairs were chosen to span intron-exon splice boundaries, RT reactions were conducted in parallel omitting the reverse transcriptase enzyme, or both. An additional control was performed by incubating an aliquot of the PCR mixture without the RT template.
Quantification of the PCR products was accomplished by the use of 18S rRNA internal standards. 18S rRNA was amplified with a primercompetimer set (QuantumRNA; Ambion) yielding a band of 489 bp. Because 18S rRNA is far more abundant than the mRNA of any gene under study, the 18S amplification reaction is reduced by the addition of competimers. These primers are modified to block extension by DNA polymerase. When combined with the functional primers, they compete for annealing to the 18S rRNA and allow amplification of a reduced number of 18S rRNA molecules. To determine the correct ratio of primers to competimers to use with a given gene, a 2.5-L aliquot of the RT reaction was used in a 40-L reaction mixture containing 5 L 10ϫ PCR buffer (400 mM Tricine-KOH [pH 9.2], 150 mM KOAc, 35 mM Mg(OAc) 2 , and 37 g/mL bovine serum albumin), 4 L dNTPs (2.5 mM each), and 1 L cDNA polymerase mix (Advan-tage; Clontech). The mixture was split into five 8-L tubes each containing 1 L of gene-specific primers (5 M each) and 1 L of different 18S primer-competimer ratios (usually 1:9, 2:8, and 3:7) plus controls. PCR amplification was performed at the determined linear cycle for the gene under study in the same conditions, to yield multiplex PCR products and to allow selection of the linear range of the 18S rRNA.
For relative quantification, reactions for each gene were repeated in triplicate in conditions in which the multiplex PCR products were all in the linear range. Band intensities were captured (ChemiDoc System, including a Chemi-cooled charge-coupled device camera, PCI digitizing image acquisition board, EpiChemi II Darkroom with transilluminator, and LabWorks Software; all from UVP, Upland, CA), and transferred to a spreadsheet (Excel, Microsoft, Redmond, WA) for calculation of averages and standard errors.
RESULTS
TIGR/MYOC Induction by DEX Is HTM Specific
Total RNAs from control and DEX-treated cells corresponding to the different tissue types were analyzed by Northern blot hybridization with full-coding TIGR/MYOC cDNA and 28S control probes. Figure 1A shows the photograph of an autoradiogram from representative Northern blots containing control and DEX-treated samples. Hybridization to control, 10-day confluent HTM cells revealed the presence of a single TIGR/MYOC mRNA band of approximately 2.0 kb (Fig. 1A) . HTM treatment with 10 Ϫ7 M DEX for the same length of time showed a marked increase in TIGR/MYOC signal in the two previously described mRNA bands. 36 However, hybridization of total RNA from embryonic SkMCs, HeLa cells, and HUVECs revealed no detectable levels of TIGR/MYOC mRNA, either with or without DEX treatment. Reprobing of the blots with 28S showed that the lack of detection of TIGR/MYOC mRNA was not due to a breakdown of total RNA. Because of the poor RNA recovery of the DEX-treated HeLa cells, the noninduction of TIGR/MYOC in this cell line was reconfirmed using RT-PCR (not shown). TIGR/MYOC RNA was not detected in primary ONH astrocytes by microarray analysis. The absolute values for this gene in both uninduced and DEX-treated ONH astrocyte GeneChips resulted in "absent" calls.
Western blot analyses of protein extracts from control and DEX-treated cells were performed using TIGR/MYOC and ␤-tubulin antibodies. Results are shown in Figure 1B . With TIGR/ MYOC antibody, blots from HTM protein extracts showed a 55-kDa doublet protein, corresponding to glycosylated and nonglycosylated forms of TIGR/MYOC. 15 Treatment with 10
Ϫ7
M DEX for 10 days resulted in a significant increase of TIGR/ MYOC in HTM cells. However, analysis of protein extracts from control and DEX induced HeLa cells, HUVECs, and SkMCs, as well as ONH astrocytes, revealed faint TIGR/MYOC cross-reacting bands. In ONH astrocytes, the TIGR/MYOC protein band appears to be less intense in the DEX-treated cells. The cross-reacting band in the SkMC extracts had a slightly faster electrophoretic mobility than TIGR/MYOC. Although it is possible that some of the faint bands observed in the nonHTM cell 
Processing and Secretion of TIGR/MYOC in the Different Cell Types
Regardless of a tissue's ability to produce TIGR/MYOC natively, we wanted to determine whether the cell lines in which TIGR/MYOC was not induced by DEX possessed the intrinsic processing and trafficking machinery necessary for the posttranslational modification and secretion of TIGR/MYOC. HeLa cells, HUVECs, and SkMCs were grown to 70% to 80% confluence and infected with replication-deficient adenoviral expression vectors for both wild-type TIGR/MYOC (AdhTIG3) 15 and a truncated mutant TIGR/MYOC (AdhTIG1) 17 previously shown to be retained intracellularly in HTM cells. 17 Western blot analysis of equivalent fractions of infected pellets and supernatants revealed that in all cases, the wild-type form of TIGR/MYOC was secreted, whereas the mutant was not (Fig.  2) . As seen previously in HTM cells, 15, 17, 18 the wild-type infected cultures showed a doublet of 55 kDa in all cell types, both intracellularly and secreted into the supernatant. Similarly, when infected with truncated mutant TIGR/MYOC expression vector, all cell lines retained the protein intracellularly. The observation that the mutant TIGR/MYOC is not secreted may indicate that this pathologic mutation interrupts or cripples a common processing pathway. 17, 18 Together, these results indicate that although the DEX induction of TIGR/ MYOC is not present in other cell types, the glycosylation and secretion mechanisms for this protein are ubiquitous among the different body tissues studied.
Microarray Comparison of Genes Present in DEX-Induced ONH Astrocytes and HTM
From our RNA and protein studies we found that the DEX response of TIGR/MYOC appears to be TM tissue-specific. To identify other TM factors that could play a role in the TIGR/ MYOC secondary glucocorticoid response and/or be involved in the DEX-triggered increase of resistance, we used gene microarrays. We compared expression profiles of DEX-induced ONH astrocytes (baseline) versus DEX-induced HTM (experimental) using microarrays (U95Av2 GeneChips, n ϭ 6; Affymetrix). We searched for genes overexpressed in the HTM-DEX in comparison with ONH astrocytes-DEX. These HTMoverexpressed genes included genes from three groups: those upregulated by DEX in HTM and not upregulated (or less upregulated) in ONH astrocytes; those that were present in HTM and not in ONH astrocytes (tissue specific genes), and genes that were downregulated by DEX in ONH astrocytes and not downregulated (or less downregulated) in HTM cells.
Four different experiments-two using one human ONH astrocytes cell-cultured line (00-1LLS; denoted A1DEX and A2DEX) and two using two HTM cell-cultured lines (HTM40 and HTM41; denoted H1DEX and H2DEX)-were treated with 10 -7 M DEX for 6 to 8 days and their RNA extracted. Each of the four treated RNAs and two untreated controls (A1 and H1) were then hybridized to individual microarrays (n ϭ 6) and analyzed as described in the Materials and Methods section. Individual outputs from each of the gene chips were compared in sets of two. To identify genes that were specifically overexpressed in the HTM-DEX sample, ONH-DEX astrocytes were used as a baseline. A total of four paired comparisons were performed: A1DEX versus H1DEX, A1DEX versus H2DEX, A2DEX versus H1DEX, and A2DEX versus H2DEX. Additional comparisons using the untreated control (H1 versus H1DEX and A1 versus A1DEX) were also performed.
The number of genes with intensities in the chips that resulted in absolute values classified as present (P) by the manufacturer's algorithms (Affymetrix) were calculated for the A1DEX and H1DEX chips. From the 12,627 genes measured on each microarray, we found that 6099 genes were expressed in the A1DEX cell line, whereas 4751 genes were expressed in the H1DEX. Within the set of genes expressed in H1DEX-treated cells, 458 genes were not expressed at any detectable levels in A1DEX-treated cells. We called these genes "turned on" in H1DEX. Similarly, 1806 genes that showed expression in the A1DEX astrocytes were not detected in H1DEX and were designated "turned off" in H1DEX. A total of 4292 genes showed expression in both induced cell types.
Genes with Expression Levels Changing More Than 20-fold in Comparing ONH Astrocytes-DEX with HTM-DEX
To identify those genes with expression levels that were the most changed (either most increased or most decreased) in HTM-DEX compared with ONH astrocytes-DEX cells, we used fold change analysis. Fold change values were calculated as the ratio of the mean expression levels of each gene between HTM and ONH astrocyte DEX-treated cell cultures. We identified 503 genes that were overexpressed and 1227 genes that were underexpressed in the HTM-DEX cells. Those genes with expression levels that changed by more than 20-fold in the HTM-DEX cells compared with ONH astrocyte-DEX are shown in Table 1 . All but one of the 40 genes showing a more than 20-fold increase were genes of known function. Four of the 18 genes with expression decreased more than 20-fold were unknown expressed sequence tags (ESTs). Very few if any of these genes were housekeeping genes and at least one fourth of them seemed to be involved in extracellular functions.
To reduce the number of genes for further analysis, we focused on those with the most increased expression. To do so, we searched for those genes showing the highest fold change values not only in one, but in all four ONH-DEX (baseline) versus HTM-DEX (experimental) comparisons (as described earlier). Because of the wide variability of fold change values among the four comparisons, we established a stringent criterion. We selected only those genes with fold change values of five or higher in at least three of the four 
Classification of the Most Overexpressed HTM-DEX-Specific Genes
The genes identified on Table 2 were categorized into three groups defined as follows: genes induced by DEX in HTM and not induced (or less induced) in ONH astrocytes (group a), genes present in HTM and not present in ONH astrocytes (group b, tissue specific genes) and genes downregulated by DEX in ONH astrocytes and not downregulated (or less downregulated) in HTM (group c).
To categorize the genes from Table 2 into these three groups, we made use of the comparison analysis obtained with the microarrays from HTM uninduced versus HTM-DEX, ONH astrocytes uninduced versus ONH-DEX, and HTM uninduced versus ONH astrocytes uninduced (H1 versus H1DEX; A1 versus A1DEX; A1 versus HTM). We found that most genes (12 out of 15) belonged to group a. Of these, nine were induced by DEX in HTM but not in ONH astrocytes, and three (IGFBP2, AKR1C3, and AP1G1) were induced by DEX in both cell lines (higher in HTM). Two genes belonged to group b. Of these, one (AKR1C1), was overexpressed in uninduced HTM versus uninduced ONH astrocytes (tissue specific) and further overexpressed by DEX in the HTM cells but not in ONH astrocytes; the second gene (ASS) was only HTM tissue-specific and its expression was not induced by DEX. Only one gene belonged to group c. This gene, PCOLCE, was severely downregulated in ONH astrocytes treated with DEX but showed no change with DEX in HTM cells.
In addition to TIGR/MYOC, 8 of the 15 genes differentially overexpressed in HTM-DEX encode secreted glycoproteins. These include: ␣1-antichymotrypsin (ACT) a serine protease inhibitor (serpin) involved in neurodegenerative diseases 37 ; pigment epithelium-derived factor (PEDF), an RPE-secreted glycoprotein with a neuroprotective role 38 ; type I procollagen C-proteinase enhancer (PCOLCE), a procollagen binding protein that affects synthesis of collagen type I 39 ; human cartilage protein GP-39, a secretory product of chondrocytes, highly abundant in cartilage and a marker for joint disease 40 ; corneaderived transcript 6 (CDT6), involved in increased ECM deposition and antiangiogenesis 41 ; prostaglandin D2 synthase (PGD2S), responsible for the conversion of prostaglandin H 2 into prostaglandin D 2 (PGD 2 ), a hormone that inhibits release of nitric oxide (NO) and induces vasodilatation 42 ; aldoketoreductase 3 (AKR1C3), an enzyme that catalyzes the conversion of PGD 2 to prostaglandin F 2 (PGF 2 ); 43 and finally, apolipoprotein D (APOD), a lipocalin shown to accumulate in the cerebrospinal fluid of patients with neurologic diseases, such as Alzheimer, multiple sclerosis, and schizophrenia. 44, 45 The nonsecreted proteins identified by our criteria include metabolic enzymes, (AKR1C1 and ASS), an actin (ACTG2), and proteins involved in mitochondrial transport (CTP) and trafficking (AP1G1).
RQ RT-PCR Confirmation of Differentially Expressed Genes
Five selected genes identified as being differentially expressed according to the parameters of the microarray system (Affymetrix) were further analyzed by RQ RT-PCR, using H1DEX and A1DEX total RNA. The primers used for the amplifications are shown in Table 3 , and the amplified products in Figure 3 . For each of the genes measured by RQ RT-PCR, the mRNA levels were shown to change in the same direction as the changes measured by the microarray detection. However, the fold change values showed a higher dynamic range, a phenomenon also known to occur between relative quantitative PCR and microarrays. 46 The expression of TIGR/MYOC and PGD2S was not detected by PCR in ONH astrocytes-DEX, agreeing with the absence call obtained in the arrays. In the TIGR/ MYOC panel, the TIGR/MYOC reaction loaded in the gel was diluted 100ϫ. Assuming a minimal number for densitometry detection of the A1DEX band, the change calculation would result in a TIGR/MYOC H1DEX overexpression of approximately 315-fold. Overexpression of ␣1-antichymotrypsin was calculated to be 54 Ϯ 1.1 higher. In the PEDF panel, the PEDF reaction loaded in the gel was diluted 100ϫ, resulting in a calculated change multiple of overexpression in the HTM of 111 Ϯ 3.5. Last, in the PCOLCE panel, the overexpression of this gene by this method was found to be 1.5 Ϯ 0.1.
HTM-DEX-Specific Genes Located in Regions Linked to Glaucoma
Because glaucoma develops in some patients treated with corticosteroids, we were interested to know how many of the specific HTM-DEX-upregulated genes would map to chromosomal regions linked to glaucoma. Comparison of A1DEX versus H1DEX revealed that 249 genes were differentially overexpressed in HTM-DEX with fold change values higher than 4.
Locus Link database mapping of each of those genes, together with examination of known glaucoma-linked regions listed in OMIM (as of January 24, 2002) , produced an overlap of 15 genes (Table 4) . Of these 15 genes, only the TIGR/MYOC gene has thus far been linked to glaucoma. 2 Two additional genes, angiopoietin like-factor CTD6 and type I membrane associated glycoprotein T1A-2 are significantly induced by DEX only in the HTM. Optineurin, (labeled as FIP2 in the microarray chip; Affymetrix) a gene recently linked to glaucoma, was not overexpressed in H1DEX versus A1DEX.
DISCUSSION
Although TIGR/MYOC is expressed in many different tissues in the body, mutations in TIGR/MYOC have thus far been associated only with glaucoma. How mutations in this widely expressed protein cause disease only in the eye is not yet understood. 
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Our results showing that altered processing and secretion of the mutant occurring across cell types are an indication that these characteristics, per se, are not responsible for the disease. Current hypotheses on the pathologic nature of TIGR/ MYOC focus on the abnormal intracellular accumulation of the mutant protein in the TM cells 15 and thus in a gain of function. 15, 19 An intracellular accumulation of TIGR/MYOC mutant protein resulting in a pathologic condition in the TM and not in other tissues could be caused by a tissue-specific overexpression of a gene in response to certain insults. Similarly, the disease could be triggered by the specific induction of a particular cellular trait that would make these cells less tolerable to defective protein accumulation. Studying the differential induction of TIGR/MYOC in the TM could then provide an insight as to what causes glaucoma to develop in patients with mutated TIGR/MYOC.
In this study, we report that the distinguishing feature of TIGR/MYOC in the TM is its marked induction with glucocorticoid treatment. TIGR/MYOC RNA and protein levels increase in HTM after 7 to 10 days of DEX treatment but do not increase in any of the other tested cells. TIGR/MYOC was also reported not to be induced by DEX on porcine astrocytes. 25 We believe this TIGR/MYOC tissue-specific property may be able to elucidate the linkage of this protein to glaucoma only.
Having identified the specific TIGR/MYOC induction, we set out to find other TM factors that were present in DEXinduced HTM cells and barely present or absent in other tested DEX-induced cells, including ONH astrocytes, a key cell type involved in ONH remodeling in glaucoma. 26 We reasoned that their specific presence in HTM-DEX could be involved in overexpression of TIGR/MYOC or be independently relevant in steroid-induced elevated IOP. Using microarray technology (GeneChip; Affymetrix), we compared expression profiles of HTM cells and ONH astrocytes induced with DEX.
In addition to confirming our TIGR/MYOC findings, the microarray studies further identified approximately 600 genes with expression levels in HTM-DEX in comparison with ONH astrocytes-DEX had fold change values higher than plus four or lower than minus four. To narrow our selection, we implemented filters on the fold change expression. Our focus was, rather than to define an actual fold change value, to select those genes that exhibited the highest overexpression. Because of the variability of fold change values observed among the compared cell lines, we applied a stringent criterion and selected only genes with values higher that fivefold (values of twofold are significant) in three of four comparisons. We think this observed variability is mostly due to the distinct response of a given gene to insults in different individuals. 36 Our criteria identified 15 genes, most of which encode secreted glycoproteins. Although we do not know the particular role of these proteins in the TM, their reported known functions appear to have potential relevance to the regulation and maintenance of IOP.
Because of the important role of the abundance and composition of ECM in the physiology of TM, 47, 48 an induction of functional serine protease inhibitors such as ␣1-antichymotrypsin would result in increased ECM deposition and decreased degradation in the TM. Furthermore, ␣1-antichymotrypsin is associated with formation of amyloid plaques 37 in aged and Alzheimer-affected brains. 49, 50 It seems possible that the presence of plaques or extracellular aggregates observed in the HTM of steroid-induced glaucoma 51 is influenced by the HTM DEX-induced expression of this powerful serpin.
Because of their clear role in other tissues, two of the other glycoproteins identified, CDT6 and human cartilage GP39, may also influence the composition of the ECM in the DEX-induced TM. It is well established that the TM from human anterior segments perfused with DEX, as well as that of patients diagnosed with corticosteroid-induced glaucoma, has a distinct morphology, with thickened trabecular beams, decreased intratrabecular spaces and an increased amount of extracellular materials. 51, 52 It is further intriguing that CDT6, a relatively new corneal protein, maps to chromosomal region 1p36, where the GLC3B region has been associated with a recessive form of congenital glaucoma. 53 We had previously reported GP-39 as one of the most abundant clones in an HTM library from a normal individual. 54 Its specific induction with DEX reinforces the relevance of this protein in the TM.
The specific induction of PEDF in the TM is intriguing. Its reported protection of neurons from apoptosis, glutamate toxicity, and especially hydrogen peroxide 38, 55, 56 leads us to speculate that perhaps this protein serves a similar protective role in the TM.
One of the two reported functions of PGD 2 synthase is the formation of PGD 2 . A synthetic analogue of PGD 2 that has been shown to reduce IOP in humans. 57 PGD 2 synthase has been detected in several ocular tissues and in aqueous humor. 58 Recently, the same enzyme has been reported to be overexpressed in ONH astrocytes cultured from glaucomatous eyes. 59 It is interesting that the expression of this gene is altered in two glaucoma-implicated cell types and under two distinct glaucomatous conditions.
In our study, two other genes encoding enzymes that regulate steroid hormone metabolism, AKR1C1 and AKR1C3, were also markedly overexpressed in HTM-DEX cultures. The role of these enzymes, also known as 3␣-hydrosteroid dehydrogenases (3␣-HSD), 60 in the HTM have been studied in detail in relation to steroid-induced elevated IOP. 61 Abnormal activity of 3␣-HSD in the HTM results in abnormal accumulation of 5␣-and 5␤-dihydrocortisol, which causes elevated IOP in rabbits, whereas their normal product, tetrahydrocortisol, was inactive. [62] [63] [64] More recently, it has been shown that primary cultures of glaucomatous ONH astrocytes exhibit extraordinary upregulation of AKR1C1 and AKR1C3 mRNA, suggesting active steroid metabolism by glaucomatous astrocytes. 59 Our current results in HTM-DEX, together with these findings, suggest for the first time a potential association between abnormal steroid metabolism in the HTM, elevated IOP, and glaucomatous optic neuropathy.
Although this study focused primarily on genes overexpressed in the TM, we have also listed those genes with expression that is most reduced in HTM-DEX, compared with ONH astrocytes-DEX. Of particular interest is the lower expression of elastin in the HTM, further confirmed by the presence of two probe sets in the microarray. This difference appears to be due to a higher abundance of the elastin gene in ONH astrocytes rather than a down-or upregulation of the gene by DEX. Using immunohistochemistry, earlier studies reported no detection of elastin in the HTM cells, with only a moderate induction of DEX. 65 In contrast, ONH astrocytes express detectable elastin mRNA in vitro and in vivo. 66 Although it has been reported that DEX suppresses elastin gene expression in skin fibroblasts in culture, 67 it has also been shown that the elastin promoter contains glucocorticoid response elements that upregulate the expression of reporter genes in transgenic mice. 68, 69 Other genes that are downregulated in DEX-HTM are associated with the central nervous system; therefore, they are more abundant in astrocytes. Among these genes are STAT1, P311, Pentraxin 1, and Serpin B2.
Most of the proteins identified in this study are secreted. As such, they have the potential to affect significantly the ECM of the TM. It is interesting to note that the known functions of these proteins point to mechanisms that could have different, possibly opposite, effects on outflow facility. The overexpression of proteins, such as ␣1-antichymotrypsin, CDT6, and cartilage GP39, seems to suggest a direct increase in ECM depo- 36 ; and perhaps PGD2S, an enzyme involved in the synthesis of an IOP-lowering prostaglandin, points to the induction of different types of defense mechanisms against increased resistance.
TIGR/MYOC was first identified as a gene upregulated in HTM cells with long-term steroid treatment in culture. The initial excitement surrounding this discovery was the prospect that this gene could be responsible for steroid-induced glaucoma. Establishing the connection between TIGR/MYOC function and pressure regulation has been difficult and remains the object of intense research and controversy. Our data show that in the cell types studied, TIGR/MYOC was significantly induced by DEX in HTM only. By comparing expression profiles, we have identified additional genes that share this tissue-specific induction. This set of genes, though far from complete, confirms at the molecular level the primacy of the role of the ECM in the development of steroid-induced glaucoma. Most important, these genes reveal the presence of new, potentially protective mechanisms that may also become activated in the cells of the HTM after treatment with DEX. Elucidation of which of those mechanisms TIGR/MYOC serves in the meshwork and of the relevance of the genes identified in this analysis remains an important challenge.
